Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

Nishimura,Reiki; Osako,Tomofumi; Okumura,Yasuhiro; Hayashi,Mitsuhiro; Toyozumi,Yasuo; Arima,Nobuyuki

doi:10.3892/etm.2010.133

Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

Authors:
- Reiki Nishimura
- Tomofumi Osako
- Yasuhiro Okumura
- Mitsuhiro Hayashi
- Yasuo Toyozumi
- Nobuyuki Arima
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan, Department of Clinical Pathology, Kumamoto City Hospital, Kumamoto 862-8505, Japan
Published online on: July 21, 2010 https://doi.org/10.3892/etm.2010.133
Pages: 747-754

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The choice of adjuvant systemic therapy is based on targeted therapy in line with the St. Gallen Consensus meeting. In addition to the traditional parameters, the panel recommended the use of proliferation markers and multigene assays. The purpose of the present study was to evaluate the clinical significance of proliferative activity using the Ki-67 index as a prognostic marker and as a predictor of recurrence time in breast cancer patients. The Ki-67 index was measured in 3,652 cases with primary breast cancer from 1987 to 2009. Out of these patients, 2,638 cases were evaluated simultaneously for estrogen receptor, progesterone receptor and HER2 from 1997, and these were analyzed as a prognostic factor according to their subtypes. The Ki-67 index exhibited a wide range of 1-99%, with a median of 20%, and cases were divided into 2 or 3 index groups; <20% and ≥20% (and ≥50%). The median Ki-67 index of tumors with luminal A was 17%, and that of luminal B type tumors was 29%. The Ki-67 index of HER2 tumors was 40% and that of triple negative tumors was 50%. A higher Ki-67 index significantly correlated with a higher grade of malignancy. Patients with a higher Ki-67 index had significantly lower disease-free survival (DFS) and overall survival rates. Moreover, there was a significant difference in the recurrence time. Multivariate analysis revealed that the Ki-67 index was a significant factor for DFS, irrespective of nodal status, and that Ki-67 was a significant marker only in luminal A type tumors. Furthermore, luminal A type cases with high Ki-67 had a similar DFS as the luminal B type cases. A higher Ki-67 index (≥20%) significantly correlated with other biological markers, poorer prognosis and early recurrence, particularly in luminal A type tumors. It is important to take the Ki-67 index into consideration in the treatment and follow-up of breast cancer patients.

View Figures

View References

1.	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ: panel members:. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
3.	Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J and Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 168:357–363. 1982. View Article : Google Scholar
4.	Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24:3726–3734. 2004. View Article : Google Scholar : PubMed/NCBI
6.	De Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI
7.	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Kai K, Nishimura R, Arima N, Miyayama H and Iwase H: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol. 11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Wiesner FG, Magener A, Fasching PA, et al: Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast. 18:135–141. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Penault-Llorca F, Andre F, Sagan C, et al: Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 27:2809–2815. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Clahsen PC, van de Velde CJ, Duval C, et al: The utility of mitotic index, estrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 25:356–363. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Weikel W, Brumm C, Wilkens C, Beck T and Knapstein PG: Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev. 19:446–450. 1995.PubMed/NCBI
14.	Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar
15.	Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 10:47–52. 1999. View Article : Google Scholar
16.	Nishimura R, Osako T, Okumura Y, Hayashi M and Arima N: Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. Sept. 4–2009.(E-pub ahead of print).
17.	Cheang MCU, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
18.	Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M and Larsimont D: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer. 44:2791–2798. 2008.
19.	Durbecq V, Desmed C, Paesmans M, et al: Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 25:1473–1479. 2004.PubMed/NCBI
20.	Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 28:1821–1828. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Chang J, Powles TJ, Allred DC, et al: Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 6:616–621. 2000.PubMed/NCBI
22.	Makris A, Powles TJ, Allred DC, et al: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat. 48:11–20. 1998. View Article : Google Scholar : PubMed/NCBI
23.	Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M and Walsh G; IMPACT Trialists Group: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 99:167–170. 2007. View Article : Google Scholar